カテゴリ： GlobalData, フランス, 企業調査

Laboratoires Pierre Fabre SA-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Laboratoires Pierre Fabre SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012227
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：84
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. The company’s products address the full spectrum of health care needs from pathologies such as cancer or atopical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands which include Derma, Galenic Klorane, Avene, Ducray, Rene Furterer, and others. Pierre Fabre is headquartered in Ile-de-France, France.

Laboratoires Pierre Fabre SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2011 to YTD 2017 12
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17
Pierre Fabre Acquires Desogestrel from Helm Medical 18
Pierre Fabre Acquires Clareal from Helm Medical 19
Pierre Fabre Acquires Batrafen Shampooing Assets from Sanofi 20
Partnerships 21
Pierre Fabre Enters into Distribution Agreement with Medinova 21
Institut Curie Enters into Agreement with Pierre Fabre 22
Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 23
Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 24
Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 25
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 26
Pierre Fabre Pharma Enters into Co-Marketing Agreement with Grupo Biotoscana 27
Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28
Evotec Partners with Pierre Fabre Labs 29
Pierre Fabre Partners with VibioSphen 30
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32
Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33
Pierre Fabre Medicament Partners with Inserm Transfert 34
Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35
Pierre Fabre Partners with Biomax Informatics 36
AbCheck Expands Research Agreement with Pierre Fabre Pharma 37
Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38
Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39
AbCheck Enters Into Research Agreement With Pierre Fabre 40
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42
Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44
Pierre Fabre Enters into Agreement with Geiser Pharma 45
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46
Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47
ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48
Licensing Agreements 49
Substipharm Enters into Licensing Agreement with Pierre Fabre 49
Pierre Fabre Enters into Licensing Agreement with Hill Derma 50
Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 51
Darya-Varia Enters into Licensing Agreement with Pierre Fabre 52
Pierre Fabre Enters into Licensing Agreement with Lonza 53
Pierre Fabre Enters into Licensing Agreement with Lonza 54
Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 55
Pierre Fabre Enters into Licensing Agreement with Medis 56
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 57
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 58
Pierre Fabre Enters into Licensing Agreement with PLEURAN 59
Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 60
Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 61
Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 62
Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 63
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 64
Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 65
Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 66
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 67
Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 68
Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 69
Pierre Fabre Enters into Licensing Agreement with Losan Pharma 70
Pierre Fabre Enters into Licensing Agreement with Fidia Farmaceutici 71
MediGene Enters Into Licensing Agreement With Pierre Fabre For Veregen 72
Equity Offering 73
TargeOn Raises Funds through Private Placement of Shares 73
Asset Transactions 74
Amatsigroup Acquires R&D Center from Pierre Fabre Labs 74
Acquisition 75
Pierre Fabre Sells 6% Stake In Boiron For US$42 Million 75
Laboratoires Pierre Fabre SA – Key Competitors 76
Laboratoires Pierre Fabre SA – Key Employees 77
Laboratoires Pierre Fabre SA – Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Affiliate 81
Recent Developments 82
Product News 82
May 09, 2016: Matwin And Pierre Fabre Fund For Innovation Strengthen Their Partnership To Boost The Development Of Innovative Projects In Oncology 82
Other Significant Developments 83
Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 83
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84

List of Tables
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Laboratoires Pierre Fabre SA, Deals By Therapy Area, 2011 to YTD 2017 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2011 to YTD 2017 12
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17
Pierre Fabre Acquires Desogestrel from Helm Medical 18
Pierre Fabre Acquires Clareal from Helm Medical 19
Pierre Fabre Acquires Batrafen Shampooing Assets from Sanofi 20
Pierre Fabre Enters into Distribution Agreement with Medinova 21
Institut Curie Enters into Agreement with Pierre Fabre 22
Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 23
Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 24
Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 25
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 26
Pierre Fabre Pharma Enters into Co-Marketing Agreement with Grupo Biotoscana 27
Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28
Evotec Partners with Pierre Fabre Labs 29
Pierre Fabre Partners with VibioSphen 30
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32
Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33
Pierre Fabre Medicament Partners with Inserm Transfert 34
Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35
Pierre Fabre Partners with Biomax Informatics 36
AbCheck Expands Research Agreement with Pierre Fabre Pharma 37
Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38
Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39
AbCheck Enters Into Research Agreement With Pierre Fabre 40
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42
Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44
Pierre Fabre Enters into Agreement with Geiser Pharma 45
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46
Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47
ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48
Substipharm Enters into Licensing Agreement with Pierre Fabre 49
Pierre Fabre Enters into Licensing Agreement with Hill Derma 50
Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 51
Darya-Varia Enters into Licensing Agreement with Pierre Fabre 52
Pierre Fabre Enters into Licensing Agreement with Lonza 53
Pierre Fabre Enters into Licensing Agreement with Lonza 54
Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 55
Pierre Fabre Enters into Licensing Agreement with Medis 56
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 57
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 58
Pierre Fabre Enters into Licensing Agreement with PLEURAN 59
Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 60
Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 61
Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 62
Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 63
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 64
Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 65
Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 66
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 67
Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 68
Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 69
Pierre Fabre Enters into Licensing Agreement with Losan Pharma 70
Pierre Fabre Enters into Licensing Agreement with Fidia Farmaceutici 71
MediGene Enters Into Licensing Agreement With Pierre Fabre For Veregen 72
TargeOn Raises Funds through Private Placement of Shares 73
Amatsigroup Acquires R&D Center from Pierre Fabre Labs 74
Pierre Fabre Sells 6% Stake In Boiron For US$42 Million 75
Laboratoires Pierre Fabre SA, Key Competitors 76
Laboratoires Pierre Fabre SA, Key Employees 77
Laboratoires Pierre Fabre SA, Other Locations 78
Laboratoires Pierre Fabre SA, Subsidiaries 79
Laboratoires Pierre Fabre SA, Affiliate 81

★海外企業調査レポート[Laboratoires Pierre Fabre SA-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • CAE Inc (CAE)：企業の財務・戦略的SWOT分析
    CAE Inc (CAE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Korres Natural Products SA：戦略・SWOT・企業財務分析
    Korres Natural Products SA - Strategy, SWOT and Corporate Finance Report Summary Korres Natural Products SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Liberty Petroleum Corp：石油・ガス：M&Aディール及び事業提携情報
    Summary Liberty Petroleum Corp (Liberty) is an independent energy company that explores and develops oil and natural gas reserves. The company provides petroleum exploration properties such as onshore Cooper Eromanga Basin, offshore Gippsland Basin and offshore Browse Basin, among others. It holds p …
  • Independent News & Media PLC (IPDC)：企業の財務・戦略的SWOT分析
    Independent News & Media PLC (IPDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • HOCHTIEF AG：戦略・SWOT・企業財務分析
    HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report Summary HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Parion Sciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Parion Sciences Inc (Parion Sciences) is a development stage company that provides research, development and commercialization of treatments to improve patient’s innate mucosal surface defenses. The company’s pipeline products include P-1037, a clinical stage ENaC blocker for pulmonary disea …
  • GlycoNex Inc (4168)：製薬・医療：M&Aディール及び事業提携情報
    Summary GlycoNex Inc (GlycoNex) is a drug discovery company that conducts research and development in glycosphingolipid antigen and human monoclonal antibody technologies to develop cancer drugs. The company carries out antibody drug development through its various technology platforms such as glyco …
  • Petro-Hunt LLC：石油・ガス：M&Aディール及び事業提携情報
    Summary Petro-Hunt LLC (Petro-Hunt) is an oil and gas exploration and production company. The company offers services in the areas of pipeline exploration and production; gas processing, oil and gas technology; refining, real estate and ranching. Its exploration and production activities include dri …
  • CP Kelco：企業の戦略・SWOT・財務情報
    CP Kelco - Strategy, SWOT and Corporate Finance Report Summary CP Kelco - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Aurizon Holdings Limited：企業の戦略・SWOT・財務情報
    Aurizon Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Aurizon Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vaccinex Inc (VCNX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Vaccinex Inc (Vaccinex) is a clinical-stage biotechnology company that discovers and develops targeted biotherapeutics to treat neurodegenerative diseases, cancer and autoimmune disorders. The company’s lead platform technologies include antibody platform and ActivMAb, SEMA4D, and antibody d …
  • International SOS Pte Ltd：企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Laboratorio Reig Jofre SA-製薬・医療分野：企業M&A・提携分析
    Summary Laboratorio Reig Jofre SA (Reig Jofre) is a drug company that develops and manufactures medicinal products and nutritional supplements. The company’s product categories include specialized technology products, specialty therapeutic areas, and nutritional supplements and consumer healthcare. …
  • Carbonite Inc (CARB)：企業の財務・戦略的SWOT分析
    Summary Carbonite Inc (Carbonite) is a subsidiary of Open Text Corporation, is a software development company that provides cloud and hybrid backup products and solutions. The company provides automatic backup solutions for home including personal basic, personal prime, and personal plus, among othe …
  • Lebara Group：企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Glenmark Pharmaceuticals Limited：企業のM&A・事業提携・投資動向
    Glenmark Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Glenmark Pharmaceuticals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • PDS Biotechnology Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary PDS Biotechnology Corp (PDS Biotechnology) is a biopharmaceutical company that develops vaccines and immunotherapies for cancer and infectious disease. The company uses versamune technology that is immunostimulatory nanoparticle vaccine platform used for the development of cancer immunothera …
  • Cullinan Holdings Limited
    Cullinan Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Cullinan Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Business Development Bank Of Canada
    Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report Summary Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • KLA-Tencor Corporation (KLAC)：企業の財務・戦略的SWOT分析
    KLA-Tencor Corporation (KLAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆